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Abstract
Background
Delayed-release dimethyl fumarate (DMF) has demonstrated ro-
bust efficacy in treating patients with relapsing-remitting multiple
sclerosis. Decreases in absolute lymphocyte count (ALC) are
a well-known pharmacodynamic effect of DMF treatment, but-
lymphocyte recovery dynamics are not well characterized after
discontinuation of DMF.
Methods
Data sources included the Biogen DMF integrated clinical trial data
set, a retrospective US chart abstraction study, and data from
MSBase. We assessed rate and time course of lymphocyte re-
constitution after DMF discontinuation.
Results
The majority of patients who developed lymphopenia while treated with DMF and sub-
sequently discontinued treatment experienced ALC reconstitution. The median time to reach
ALC ≥0.8 × 109/L was 2–4 months after discontinuation for patients treated in real-world data
sets; the median time to reach ALC ≥0.91 × 109/L was 2 months after discontinuation in DMF
clinical trials. Severity of lymphopenia on treatment and decline in ALC within the first 6
months did not affect the ALC reconstitution rate after DMF discontinuation; rather, on-
treatment lymphopenia duration influenced the reconstitution rate. In patients with severe,
prolonged lymphopenia for ≥3 years, lymphocyte reconstitution to ≥0.91 × 109/L was 12–18
months vs 2–3 months in patients with lymphopenia persisting <6 months.
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Conclusions
The majority of patients who discontinued DMF due to lymphopenia experienced ALC reconstitution within 2–4 months
following DMF discontinuation. This may help guide clinicians in managing patients who develop lymphopenia during DMF
treatment. Prolonged lymphopenia on DMF treatment is associated with slow lymphocyte recovery after DMF discontinuation.
Delayed-release dimethyl fumarate (DMF) is an effective treat-
ment in patients with relapsing forms of multiple sclerosis
(MS),1–4 with a well-characterized safety profile.5,6 Decreased-
lymphocyte counts are a pharmacodynamic effect of DMF.7 In
the first year of treatment in pivotal phase 3 trials (DEFINE/
CONFIRM), absolute lymphocyte counts (ALCs) declined
;30% and then stabilized,7 regardless of baseline ALC.8 ALCs
remained above lower limit of normal (LLN; 0.91 × 109/L) for
76% of patients in the first year of treatment.9 Few (2%) DMF-
treated patients experienced severe, prolonged lymphopenia
(ALC <0.5 × 109/L for ≥6 months).7 As of August 31 2019,
there were >425,000 patients treated with DMF worldwide,
representing >810,000 patient-years of exposure; to date, the
rate of progressive multifocal leukoencephalopathy (PML) with
DMF-treatment was estimated as <1/100,000 patient-years. The
majority of cases of PML occurred in the setting of moderate
(<0.8 × 109/L) or severe, prolonged lymphopenia.10,11 To
minimize potential risks of prolonged moderate-to-severe lym-
phopenia, DMF labels recommend monitoring lymphocyte
counts every 6–12 months after DMF initiation and considering
DMF discontinuation for patients with severe, prolonged lym-
phopenia. In an integrated clinical trial analysis, including patients
followed for up to 11 years, aside from 1 case of PML, there was
no increased incidence of malignancy, or opportunistic or serious
infection, regardless of on-treatment ALC or T-cell subset
count.12–14
Limited data are available describing lymphocyte dynamics in
patients who develop lymphopenia and subsequently dis-
continue DMF. Using clinical trial and real-world data, we
assessed the lymphocyte reconstitution rate and time course
after DMF discontinuation and time to initiating sequential
therapy for patients with lymphopeniawho discontinuedDMF.
Methods
In patients with relapsing-remitting MS treated with DMF
who developed lymphopenia and subsequently discontinued
DMF, lymphocyte reconstitution was assessed using 3 dis-
tinct data sources: (1) an integrated analysis of DMF clinical
trials, and real-world patient data collected via phase 4 ret-
rospective chart abstraction study from (2) five US centers
and (3) the MSBase registry.
MSBase is an international, online registry designed to collect
prospective data on patientswithMS. Participating neurologists
contribute data on diagnosis, treatment, and progress, thereby
facilitating collaborative research through investigator-initiated
substudies. To date, 22 neurologists from 11 countries have
contributed data from 2,400 patients. The MSBase sites are
separate from the relevant US centers included in the chart
abstraction study.15
Integrated analysis of DMF clinical trials
The integrated analysis of DMF clinical trials (DMF in-
tegrated clinical trials) comprised a phase 2b study
(NCT00168701), the phase 3 DEFINE (NCT00420212),
and CONFIRM (NCT00451451) studies, and the EN-
DORSE (NCT00835770) extension study, including data as
of 01 September 2017 (n = 2,513 patients). Blood collection
(including ALC) while on treatment occurred at least every
12 weeks. ALC grades according to the Common Termi-
nology Criteria for Adverse Events v4.0 were as follows:
grade 0 (≥LLN, ≥0.91 × 109/L); grade 1 (<LLN to ≥0.8 ×
109/L); grade 2 (<0.8 to ≥0.5 × 109/L); grade 3 (<0.5 to
≥0.2 × 109/L); and grade 4 (<0.2 × 109/L).
For patients with ALC < LLN at DMF discontinuation, ALCs
were collected at least every 12 weeks, until ALC returned to
LLN (ALC <0.91 × 109/L) or the patient discontinued the
study. Patients with an ALC < LLN at DMF discontinuation
and ≥1 post-DMF ALC value or who temporarily discontinued
DMF but did not experience severe, prolonged lymphopenia
were included in lymphocyte reconstitution analyses (N =
138). Patients with severe, prolonged lymphopenia (<0.5 ×
109/L for ≥6 months) were analyzed separately due to the
prolonged duration of on-treatment lymphopenia (N = 38).
The product label recommendation to consider treatment in-
terruption in patients with severe, prolonged lymphopenia was
added to the protocol after the study had been ongoing ;7
years. Therefore, this cohort is not considered representative of
current real-world DMF use because some clinical trial patients
experienced lymphopenia for longer than would be expected
with current recommendations.10
For the reconstitution analysis, patients were stratified by the
following: (1) lowest ALC recorded on DMF treatment or
ALC at discontinuation: <0.5 × 109/L, ≥0.5 to <0.8 × 109/L,
and ≥0.8 to <0.91 (LLN) × 109/L; (2) median ALC at dis-
continuation: ≤median (0.73 × 109/L) and > median (0.73 ×
109/L); and (3) ALC in the first 6 months of DMF treat-
ment: any ALC <0.8 × 109/L and always ≥0.8 × 109/L.
MSBase/US chart review
This phase 4 retrospective chart abstraction study included
retrospective medical record review data (April 2017–March
2018) from 5 US centers and MSBase registry data as of No-
vember 17, 2017. The primary end point was the ALC change
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over time. Key inclusion criteria included treatment with DMF
for 3–24 months, as per standard of care, and DMF discon-
tinuation for any reason; baseline ALC > LLN (0.91 × 109/L);
≥2 ALC assessments of <LLN during DMF treatment; and ≥2
ALC assessments after DMF treatment, ≥1 recorded ≥90 days
after DMF discontinuation. Included patients had ALC < LLN
at discontinuation. Patients treated with DMF for ≥2 years
were excluded to obtain patients whose exposure to DMF was
less than that of the integrated clinical trials.
Statistical methods
For the DMF integrated clinical trials, a linear mixed-effect
model with random intercept and random slope of time (in
weeks) was used to assess slope of ALC reconstitution after
DMF discontinuation, adjusted for age and ALC group at
discontinuation, and an interaction between time and ALC
group. Estimated overall slope is based on a linear mixed-
effect model, adjusted only for age.
ForMSBase andUS chart review, slopes of ALC reconstitution
in the first 12 weeks after DMF discontinuation were calculated
using a linear mixed-effect model of ALC measures with ran-
dom intercept and random slope of time, in weeks, adjusted for
age and ALC group at discontinuation (<0.5 × 109/L or ≥0.5 ×
109/L) as well as interaction between time and ALC group.
Standard protocol approvals, registrations,
and patient consents
For the DMF integrated clinical trials, the studies were ap-
proved by central and local ethics committees and conducted in
accordance with International Conference on Harmonization
Guidelines for Good Clinical Practice and the Declaration of
Helsinki.2–4,6 All patients provided written informed consent.
For the MSBase/US chart review, the local institutional review
board at each institution approved these studies.
Data availability
Anonymized data can be shared at the request of qualified
investigators for purposes of replicating procedures and results.
Results
In the DMF integrated clinical trials, as of September 1, 2017,
the lymphocyte analysis population consisted of 2,470
patients (10,971 patient-years of follow-up) with ≥1 post-
baseline ALC recorded. The DMF integrated clinical trials of
patients with ALC < LLN at DMF discontinuation and ≥1
post-DMF ALC value—excluding patients with severe,
prolonged lymphopenia—represent 5.5% (138/2513) of the
overall analysis population (table). Of the 138 patients, the
DMF treatment duration was the median (range) of 35.6
(3–117) months; follow-up ranged from 0.1 to 34.3 months
for the entire population.
The primary reason for treatment discontinuation was adverse
events (30% of patients, n = 42); of these patients, the majority
discontinued due to low lymphocyte counts or white blood cell
counts (26%, n = 11) or tolerability events, including GI or
flushing and flushing-related events (26%, n = 11). The mean
(SD) baseline ALCwas 1.7 (0.5) × 109/L. Themedian (range)
minimum ALC on DMF treatment was 0.6 (0.2–0.9) × 109/L,
representing a 63% median reduction from baseline. The me-
dian time to onset of lymphopenia (first ALC <0.91 × 109/L)
was 6.2 months after DMF initiation. At discontinuation, the
median (range) ALC was 0.73 (0.29–0.90) × 109/L. After
DMF discontinuation, the median time (range) of follow-up
was 1.25 (0.10–34.3) months.
In the MSBase and US chart review analysis, data from 74
patients (184 patient-years) were evaluated, and 33 patients
met the inclusion criteria (US centers, 27; MSBase, 6); the
median (range) age was 52 (20–75) years; the median
(range) baseline ALC was 1.6 (1.0–3.9) × 109/L (table).
Patients were treated with DMF for a median (range) of 17.8
(4.8–23.9) months; the primary reason for discontinuation
was lymphopenia (61% of patients who discontinued). The
median (range) minimum ALC on DMF treatment was 0.5
(0.2–0.8) × 109/L, representing a 71% median reduction
from baseline. The median time to onset of lymphopenia
(first ALC <0.91 × 109/L) was 5.3 months after DMF ini-
tiation. The median (range) ALC was 0.5 (0.2–1.0) × 109/L
at discontinuation. After DMF discontinuation, the median
(range) follow-up period was 10.1 (3.3–31.8) months.
ALC after discontinuation
In the DMF integrated clinical trials, 138 patients had mild or
moderate lymphopenia at any time while on DMF. From
DMF discontinuation and thereafter, nearly all patients (99%
[137/138]) maintained an ALC of ≥0.5 × 109/L, and 62%
(86/138) reached an ALC ≥ LLN (≥0.91 × 109/L) in the
recovery period (figure 1A). Of the 52 patients who did not
reach LLN, 39 discontinued the study and were lost to
follow-up before reaching this milestone. After DMF dis-
continuation, ALC levels were restored to LLN within 2
months, on average. Of the 86 patients who had ALC <0.91
at DMF discontinuation and reached an ALC of LLN, the
median time to reach ALC ≥0.91 × 109/L was 7 weeks, based
on Kaplan-Meier estimates. The median time to reach an
ALC of ≥0.8 × 109/L was 6 weeks for patients who had ALC
<0.8 × 109/L at DMF discontinuation.
In MSBase and US chart review, the first median (range) ALC
measurement >3months (10.1 [3.3–31.8]months of follow-up)
after DMF discontinuation was 0.8 (0.1–2.2) × 109/L. Nearly all
Limited data are available
describing lymphocyte dynamics in
patients who develop lymphopenia
and subsequently discontinue DMF.
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patients (97% [31/32]) reached an ALC of ≥0.5 × 109/L after
DMF discontinuation, and 53% (17/32) reached an ALC ≥
LLN (figure 1B). Of the 15 patients who did not recover to LLN
after DMF discontinuation, 4 switched to other disease-
modifying therapies (DMTs) that could have affected their re-
covery (2 fingolimod and 2 rituximab). The 11 patients who did
not switch to DMTs known to markedly deplete lymphocytes
reached a median (range) 0.83 × 109/L (0.4–0.9) during the
follow-up period and no longer had ALCs recorded. Four
patients were untreated during this period; 3 treated with teri-
flunomide, 3 with an interferon, and 1 with an undefined DMT.
Of patients with ≥1 ALC <0.8 × 109/L on treatment (n = 32),
the majority (78%, 25/32) had ≥1 post-treatment ALC ≥0.8 ×
109/L. Based on Kaplan-Meier estimates, the median time from
DMF discontinuation to reach ALC ≥0.8 × 109/L (n = 25/32)
was 17weeks. Themedian time to reach anALCof≥0.91×109/L
(n = 18/32) was 46 weeks (11.5 months) for patients who
had ALC <0.8 × 109/L on DMF treatment.
Predictors of recovery after
DMF discontinuation
On-treatment lymphopenia severity was not associated with
the rate of post-DMF ALC reconstitution, but did influence
the time to restore ALC to LLN. For the DMF integrated
clinical trials, the recovery rate was similar regardless of ALC
at discontinuation (slope 0.035 for > median ALC [0.73 ×
109/L] vs 0.043 for ≤ median ALC at discontinuation; p =
0.504; figure 1C). Given the similar rates of recovery,
patients who discontinued with higher ALCs reached LLN
sooner. For patients in the DMF integrated clinical trials
who discontinued ≤ median (0.73 × 109/L), time to ALC
>0.91 × 109/L was 6.9 weeks compared with 1.5 weeks for
patients who discontinued > median based on the model.
The estimate of overall slope, excluding patients with pro-
longed lymphopenia, was mean (standard error) 0.039
(0.006), adjusted only for age; this is comparable to the
estimates of slope by the ALC subgroup (0.043 and 0.035).
Similarly, in the MSBase and US chart review, ALC levels
increased afterDMFdiscontinuation at a similar rate for 0–12
weeks, regardless of whether the last ALCwhile on treatment
was < or ≥0.5 × 109/L (median ALC at discontinuation;
slope 0.046 vs 0.032; p = 0.405; figure 1D).
Early drops in ALC have been associated with higher in-
cidence of developing severe, prolonged lymphopenia
Table Baseline characteristics of patients who discontinued DMF in theMSBase andUS chart review andDMF integrated
clinical trials
Baseline characteristic DMF integrated clinical trials (n = 138) MSBase and US chart review (n = 33)
Female, n (%) 103 (75) 28 (85)
Age at initiation, mean (SD), y 40 (8) 51 (12)
<50 122 (88) 14 (42)
≥50 16 (12) 19 (58)
Baseline ALC, mean (SD) or median
(range), × 109/L
1.7 (0.5) 1.6 (1.0–3.9)
Relapse in 12 months before DMF
initiation, mean (SD)
0.1 (0.3) 0.4 (0.8)
Previous DMT history,a n (%)
Interferon 58 (42) 23 (72)
Glatiramer acetate 12 (9) 12 (38)
Natalizumab 2 (1) 8 (25)
Fingolimod — 2 (6)
Teriflunomide — 2 (6)
Treatment naive — 5 (16)
DMF duration, median (range), mo 45 (3–117) 18 (5–24)
Discontinued DMF, n (%)b 138 (100) 33 (100)
Follow-up duration after DMF
discontinuation, median (range), mo
0.25 (0.10–34.3) 10.1 (3.3–31.8)
Abbreviations: ALC = absolute lymphocyte count; DMF = dimethyl fumarate; DMT = disease-modifying therapy; MS = multiple sclerosis.
a All known previous DMTs were collected; hence, patients could have multiple responses; for MSBase and US chart review, data were only available for 32
patients.
b Patients could have discontinued for any reason; they were included in the analysis as long as they had ALC < LLN at the time of discontinuation.
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while on treatment7; therefore, lymphocyte recovery
after DMF discontinuation was assessed by ALC levels in
the first 6 months of treatment to understand if there is
also an association with reconstitution. No such associa-
tion was observed (figure 2). Mean ALCs reached LLN
after 8 weeks of discontinuation regardless of whether
ALC levels were < or ≥0.8 × 109/L within the first 6
months of DMF treatment, although the sample size is
relatively small.
Lymphocyte recovery and clinical outcomes in
patients with severe, prolonged lymphopenia
Duration of lymphopenia was associated with a prolonged
time to reconstitution in the 38 patients with severe,
prolonged lymphopenia (figure 3). Patients with ALC
<0.5 × 109/L for ≥6 months were exposed to DMF for;6
(median) years before discontinuation. The majority,
31/38 (82%) of this small subgroup, had ALC levels <0.5
× 109/L persisting for ≥6 months by 3 years on DMF
treatment, yet treatment continued for a median of 2.9
years after ALC levels reached <0.5 × 109/L DMF dis-
continuation. While patients in the severe, prolonged
lymphopenia group achieved an ALC of ≥0.8 × 109/L
(50% [19/38]) or 0.91 × 109/L (29% [11/38]) during the
follow-up period, the median time to reach 0.8 × 109/L
was 35 weeks. Importantly, in patients followed for up to
11 years, severe, prolonged lymphopenia on treatment
(n = 53) was not associated with increased incidence of
malignancy (0.007 vs 0.004), serious herpes zoster (0 vs
0.0004), serious infection (0.017 vs 0.010), or opportu-
nistic infection (0.003 vs 0) compared with ALC ≥ LLN
(n = 1475).
Figure 1 Proportion of patients with lymphocyte reconstitution based on ALC at DMF discontinuation in (A) DMF in-
tegrated clinical trials and (B) MSBase and US chart review patients; and lymphocyte recovery after DMF
discontinuation for 0–12weeks by linearmixed-effectmodel for (C) DMF integrated clinical trials in patients ≤ or
> median ALC at discontinuation and (D) MSBase and US chart review in patients ≤ or >0.5 × 109/L ALC at
discontinuation for 12 weeks
aOnepatient did not recover to ≥0.5 × 109/L during the follow-upperiod. bOne patient did not recover to ≥0.5 × 109/L during a follow-up periodof 287 days. The
follow-up period for the 1 patient that did not recover to LLN is 8 days after DMF discontinuation. cEstimated slope 0.043 × 109/L/wk. dEstimated slope 0.035 ×
109/L/wk, p = 0.504. e0.91 × 109/L. (A and B) Patients with ALC <0.91 × 109/L at DMF discontinuation and ≥1 post-DMF ALC value were included. Patients with
<0.5 × 109/L for ≥6 months were excluded. The number of patients who achieved an ALC threshold of ≥0.7 × 109/L is included in the number of patients who
achieved an ALC threshold of ≥0.5 × 109/L. Themedian (range) follow-up period for recovery after DMF discontinuation for the entire sample (N = 33) was 10.1
(3.3–31.8) months. (C) In a linear mixed-effect model to assess slope of post-DMF ALC reconstitution, groups were determined by the last ALC recorded at or
before discontinuation. Patients with ALC <0.91 × 109/L at DMF discontinuation and ≥1 post-DMF ALC valuewere included (N = 138; n = 69 per group). Patients
with an ALC <0.5 × 109/L for ≥6 months were excluded. The median ALC at discontinuation was 0.73 × 109/L. (D) The estimated ALC reconstitution rate after
discontinuingDMFbased on repeatedmeasuresmodels for 0–12weeks (withmeasures restricted to the first 3months only). Patient estimateswere grouped
by the last ALC onDMF (assumed to bemeasured on day 1 after discontinuation); for last ALC onDMF ≥0.5 × 109/L, n = 19; for last ALC onDMF <0.5 × 109/L, n =
14. Themixed-effectmodels were adjusted for time sinceDMF discontinuation, age at discontinuation, last on-DMF ALC groups, and interaction between time
and ALC groups. Estimates at each time point were based on the fittedmodel with CIs given using Kenward-Roger approximation. p value is for the difference
in the slope estimates from the model. ALC = absolute lymphocyte count; DMF = dimethyl fumarate; MS = multiple sclerosis; LLN = lower limit of normal.
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Although the sample size is small (n = 38), the majority of
patients (71%) did not have a relapse during the 6 months
following discontinuation. For context, the unadjusted an-
nualized relapse rate (ARR) during the first 6 months after
discontinuing DMF (0.362) was generally consistent with
that of an untreated patient population; the 6-month ad-
justed ARR on placebo in DEFINE/CONFIRM was 0.430.
There was insufficient follow-up time to assess the other
groups.
Other DMTs after DMF discontinuation
Using data from MSBase and US chart review (n =
33), lymphocyte reconstitution was not significantly affected
when alternative DMTs with no known effect on lymphocyte
profiles were initiated after DMF discontinuation (figure 4, A
and B). Other DMTs were generally initiated a median
(range) of 5 (0–50) weeks after DMF discontinuation,
corresponding to median ALC >;0.8 × 109/L. Teri-
flunomide, rituximab, glatiramer acetate, and interferons
were the most common alternative DMTs initially started
after DMF discontinuation (figure 4C). No patients reini-
tiated DMF after discontinuation. The samples sizes were
too small to compare reconstitution rates by alternative
DMTs.
Discussion
Lymphocyte counts reconstituted to normal levels within
8–16 weeks if patients did not have prolonged lymphopenia
beyond 6 months. Therefore, time to ALC recovery will be
longer for patients with severe rather than mild lymphopenia
at discontinuation, confirming previous smaller studies.16,17
On average, ALC reconstitution is linear for the first 8 weeks
after DMF discontinuation, and then the recovery rate slows
(figures 2 and 4A). Lymphocyte reconstitution is influenced
by duration of severe lymphopenia on DMF, as suggested by
the 38 patients with severe, prolonged lymphopenia who
recovered to ≥LLN in ;12–18 months. The data suggest
that the lymphocyte reconstitution rate is not affected by
DMF treatment duration, lymphopenia severity, or early
drops in ALC. These results complement the findings pre-
viously reported by Mehta et al.8 While both analyses use the
same source database, data presented herein are a subset of
the population, which aligns with the real-world data set.
There are several limitations to consider. The sample size was
small for both data sets, particularly for patients treated in the
real-world setting. Unfortunately, lymphocyte counts are not
part of the minimum data set in MSBase, and the vast
Figure 2 DMF integrated clinical trials: lymphocyte re-
covery after DMF discontinuation based on ALC
decreases in the first 6 months of treatment
The mean (standard error) ALC is shown. Patients with ALC <0.91 × 109/L at
DMF discontinuation and ≥1 post-DMF ALC value were included (N = 138).
ALC = absolute lymphocyte count; DMF = dimethyl fumarate; LLN = lower
limit of normal.
Figure 3 Individual patient ALC values in patients with
severe, prolonged lymphopenia from the DMF
integrated clinical trials
The mean (standard error) ALC is shown. Patients with ALC <0.91 × 109/L at
DMF discontinuation and ≥1 post-DMF ALC value were included. Individual
patient ALC values are shown in gray. The estimated linear mean line over
time (shown in orange) was calculated using a linearmixed-effectmodel. The
severe, prolonged lymphopenia group (n = 38) was defined as patients with
ALCs <0.5 × 109/L for ≥6 months and ≥2 post-DMF ALC values. Patients were
permitted to receive alternate DMTs after discontinuation. ALC = absolute
lymphocyte count; DMF = dimethyl fumarate; DMT = disease-modifying
therapy.
Lymphocyte counts reconstituted to
normal levels within 8–16 weeks if
patients did not have prolonged
lymphopenia beyond 6 months.
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majority of DMF-treated patients do not have lymphocyte
count data available, thereby making the data sets ineligible
for analysis. However, some centers systematically
track lymphocyte counts, either spontaneously or as part of
an Australian MSBase substudy called MSFirst. In addition,
in the real-world setting, lymphocyte counts are not collected
systematically, further limiting the number of patients with
data available at specific time points in a retrospective anal-
ysis. Because reconstitution may be apparent earlier in
patients with more frequent assessments and lymphocyte
reconstitution assessments are influenced by visit schedule,
data collected from patients with sporadic visits may over- or
underestimate the time to reconstitution. Furthermore, a se-
lection bias influencing which lymphocyte recovery data are
available is possible. Together with the short duration of
follow-up after DMF discontinuation for patients in the
clinical trials, this data set has only a limited number of
patients with data available over time. However, these data,
albeit sparse, may be useful for clinicians and patients when
considering treatment discontinuation and/or a treatment
switch from DMF.
In addition, the analysis of post-treatment DMTs is limited to
a select few centers in Australia and the European Union and
likely not a true reflection of post-DMF treatment dynamics
worldwide. Because of strict inclusion criteria, the trials do
not represent the full spectrumof patients who are exposed to
DMF in routine care. This may also contribute to some
discrepancy between the data sets.
However, despite the collection differences in real-world data
compared with structured clinical trial data, the re-
constitution rate was similar for both groups. As similar in-
clusion and exclusion criteria were applied and consistent
analysis methods used, these data sets can serve as confir-
matory to each other, increasing the confidence that these
data accurately represent the true ALC recovery rate after
DMF discontinuation.
In the analysis of patients treated in the real-world setting,
inclusion of patients from the retrospective chart review was
limited to patients treated with DMF for ≤2 years, because
patients treated for a longer period were well represented in
the DMF integrated clinical trial. However, in very rare
instances, delayed lymphopenia has been noted to occur
after 2 years of therapy.18
These data on the dynamics of lymphocyte reconstitution are
important for clinicians when managing patients who de-
velop lymphopenia during DMF treatment. ALCmonitoring
is an effective tool for recognizing patients who are at risk of
prolonged moderate to severe lymphopenia.7,18 Manage-
ment of DMF-treated patients involves considerations of
when to discontinue treatment and also when and to which
alternate therapy to transition. These considerations can be
informed by understanding (1) the established pattern
Figure 4 MSBase and US chart review: (A and B) Post-
treatment lymphocyte reconstitution for
patients after discontinuing treatment with DMF
through starting another DMT and (C) post-DMF
DMTs
For patients who switched to fingolimod, natalizumab, rituximab, or
ocrelizumab after DMF discontinuation, only the ALC observations taken
before starting these treatments are included. aPatients could have se-
quentially switched to >1 DMT; only the patient’s first alternative DMT
after DMF discontinuation is shown. No patients reinstated DMF after
discontinuation. (A) The mixed-effect model regresses absolute ALC
measure on log2-transformed time (days) since discontinuation of DMF
with random intercept and slope, adjusted for age at discontinuation,
ALC group at discontinuation (<0.5 × 109/L or ≥0.5 × 109/L), and the in-
teraction between the log2-transformed time and ALC group. The last
ALC on DMF is assumed to be measured on day 1 after discontinuation. A
month is assumed to be 30 days. The estimates at each time point are
based on the fitted model with standard errors and CIs given using
Kenward-Roger approximation. (B) ALC measures are shown for in-
dividual patients, and each patient’s line ends when the patient begins an
alternate therapy. ALC = absolute lymphocyte count; DMF = dimethyl
fumarate; DMT = disease-modifying therapy; LLN = lower limit of normal.
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of lymphocyte decline during DMF treatment, (2) the effects
of DMF treatment in patients who exhibit ALC decline, (3)
the risk of DMF treatment in patients who exhibit ALC
decline, and (4) the dynamics of ALC reconstitution after
treatment discontinuation.
Although this analysis has provided some understanding of
those factors, the question remains if we can predict the ability
of lymphocyte counts to return to normal levels, as there is
variability in time of reconstitution when reviewing individual
patient-level data. For the overall population in this analysis, the
degree, magnitude, and speed of ALC decline did not influence
reconstitution in patients with severe lymphopenia for <6
months on treatment. Thus, clinicians should diligently moni-
tor ALC and consider discontinuation at the recommended
time if patients have severe, prolonged lymphopenia. Therefore,
these data demonstrate that the use of DMF per label recom-
mendations generally allows for lymphocyte recovery within
2–4 months, similar to data observed in a smaller study.16
Of the patients with severe, prolonged lymphopenia in this
analysis, there were no differences in rates of serious or op-
portunistic infections, and themajority did not have a relapse in
the 6 months after DMF discontinuation. There is no washout
recommended between stopping DMF (per country-specific
guidelines) and starting an alternate DMT. In this data set,
clinicians tended to restart an alternate DMT ;5 weeks after
DMFdiscontinuation, which coincidedwith ALC;0.8 × 109/L.
It is unclear whether time, ALC value, or another variable was
the driving factor for these decisions. Albeit small, this data set
suggests that the ARR after DMF discontinuation is similar to
that of an untreated patient population.
Themajority of patients experiencedALC reconstitutionwithin
2–4 months of DMF discontinuation. Reconstitution rate was
not significantly affected by severity of lymphopenia, including
a lower ALC at discontinuation or early drops in ALC. Patients
with longer periods and greater extent of lymphopenia expe-
rienced longer times to reconstitution. These data will inform
clinicians assessing the benefit-risk when managing patients
who develop severe lymphopenia while on DMF and in de-
veloping a personalized sequencing strategy for patients with
lymphopenia who discontinue DMF. Clinicians can use the
information on the ALC recovery rate after discontinuation to
consider next steps in DMT treatment.
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